ImpediMed (IPD) Q4 2026 earnings summary

Executive summary

• SOZO digital health platform is FDA, TGA, and CE-cleared, targeting cancer survivorship, heart failure, and weight management, with new executive leadership focused on commercial execution.

• Q4 FY26 revenue reached $3.6m, annual recurring revenue (ARR) was $14.4m, and total contract value (TCV) was $5.4m.

• 40 SOZO units sold globally in Q4, with 36 in the U.S. and 4 internationally; U.S. unit sales increased from the previous quarter.

• Reimbursement coverage increased to 95%, now covering 331 million lives in the U.S., with continued expansion in high-coverage states.

• Cash balance at quarter-end was $15.3m, supported by a $15.3m capital raise and partial loan repayment of $5.0m.

Financial highlights

• Q4 operating cash outflow was $4.9m, in line with expectations.

• Record $4.3m in cash receipts, including two large upfront payments.

• Product-related costs increased by AUD 600,000 due to inventory purchases; staff costs rose by AUD 400,000 due to one-off organizational changes.

• Renewed contract prices increased by 6.7% on average in Q4.

• Q4 ARR up 2% sequentially and 13% year-over-year in constant currency.

Outlook and guidance

• Focus on expanding the Lymphedema+ strategy, multidisciplinary cancer survivorship programs, and structured medical weight management initiatives.

• Expand heart failure sales in key reimbursed states and support clinical trials.

• Annualized cost savings of $5.0m to be realized evenly over the next year, maintaining cost discipline toward cash flow breakeven.

• Leadership confident in pathway to cash flow breakeven and sees opportunities for strategic partnerships.